You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives

    SBC: SOLANO PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. CardioPort to Enable Intracardiac Beating Heart and Minimally Invasive Open Heart Surgery

    SBC: Nido Surgical, Inc            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe goal of this Fast Track STTR project is to develop a novel CardioPortTM surgical device that will enable minimally invasive beating heart repair without use of cardiopulmonary bypassCPBThere is a critical unmet need for new instruments to improve the surgical repair of heart defects in childrenCurrent best surgical practices involve either open heart surgery wit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Developmental Disabilities Dentistry Online

    SBC: Praxis            Topic: NIDCR

    DESCRIPTION (provided by applicant): Individuals with intellectual and developmental disabilities (I/DD) have more untreated caries and a higher prevalence of gingivitis and other periodontal diseases than the general population (NIDCR, 2009). In order to address this health care disparity, more dentists are needed who understand and are trained to meet the needs of this population. Few in-depth ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. DNA helicase and primase inhibitors for biodefense

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of this project is to identify specific inhibitors of B. anthracis helicase and primase and develop them into novel antibiotics for bio-defense. New antibiotics based on novel chemical scaffolds are vital to the bio-defense armory because they are likely to be effective against both natural and engineered resistant forms of bio-terrorist agen ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 Diagnostics, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. In toto Handheld Bioagent Detector by Digital Fluidics

    SBC: Core MicroSolutions, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The design and evaluation of a handheld digital microfluidic (DMF) bioagent analyzer is proposed by Core Microsolutions (CMSS) and University of Michigan Professor K.-D. Lee (College of Pharmacy) for a two year Phase I research period in the NIH Small Business Biodefense Program. This proposed research will integrate: 1) Electrowetting on Dielectric (EWOD) drop ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced Detection Technologies for Biochips

    SBC: INDEVR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of the proposed work is the development of innovative detection technologies for biochips (a.k.a. DNA microarrays). It is envisioned that the proposed technologies will enable the application of biochips to biodefense, particularly when a rapid and reliable diagnostic screen is required in the field. The Specific Aims of the proposed wo ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government